about
Linear mixed-effect multivariate adaptive regression splines applied to nonlinear pharmacokinetics data.Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjectsPopulation pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.Bioequivalence of racemic drugs.Assessing the transport of receptor-mediated drug-delivery devices across cellular monolayersMilk transfer and toxicokinetics of valproic Acid in lactating cynomolgus monkeys.Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses.A food effect study and dose proportionality study to assess the pharmacokinetics and safety of bardoxolone methyl in healthy volunteers.Multiple-dose activated charcoal and enhancement of systemic drug clearance: summary of studies in animals and human volunteers.Enantioselective assays in comparative bioavailability studies of racemic drug formulations: nice to know or need to know?Nonlinearity detection: advantages of nonlinear mixed-effects modelingOral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast.Pharmacokinetics of rosiglitazone in patients with end-stage renal disease.Consumption of black currants, lingonberries and bilberries increases serum quercetin concentrations.Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions.No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy.To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics.Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.Effect of unbound clearance on binding parameters of valproic acid to serum proteins.Comparison of two binding equations for prediction of the concentration of unbound valproic acid in the serum of adult epileptic polytherapy patients.Distribution and pharmacokinetics of etamicastat and its N-acetylated metabolite (BIA 5-961) in dog and monkey.Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel studyPreclinical Pharmacokinetics of Scoparone, Geniposide and Rhein in an Herbal Medicine Using a Validated LC-MS/MS MethodA Compositive Strategy to Study the Pharmacokinetics of TCMs: Taking Coptidis Rhizoma, and Coptidis Rhizoma-Glycyrrhizae Radix et Rhizoma as Examples
P2860
Q31805240-57BD747D-939E-48BD-B60C-73AEA353B6F7Q34306474-124CFED0-B5C5-4194-BF0B-EB623C5E9B08Q34824085-60915207-D4EA-46E8-BFC6-70229D11DD31Q35536304-B5489234-53F9-400C-8B45-90DFE4AD309BQ35636332-CFFAEECE-50B9-4B5A-BA49-F1BF2D0B5194Q37326490-863B965F-6BE0-4E57-A6DE-1477A439C172Q37625193-0ABA7C83-8852-460D-9D29-A982043D5BB0Q39470971-EA0A8C55-0EAC-4F38-8246-BD10B9C27064Q39809966-E4DB981D-3EE4-4743-8B78-8BD5DD8F5EC3Q40468765-B8C78242-C5A4-4389-85F5-3D816F6A06D4Q41113849-B7B15406-31DC-4189-9EA8-C3B83F3A0376Q41769483-8E886746-BFBE-4E1C-8878-43B57DB52CAAQ43201527-FEF1093C-733F-4763-AF0F-A64D31255409Q44139569-F02FCB35-30B1-4622-9EC5-1F5C22A6349EQ44291589-18069194-D019-4C62-AAED-4D76F9C2C295Q44362847-EABFF5A3-55AF-4D8A-A46D-9A3C5E1E4F9DQ44526913-3ADC600C-E7FB-4F3E-B69D-2B7C0AF8E126Q45929957-0C24B021-DF05-4121-B5FB-64F32874BF8AQ50871327-5FB0830C-887E-4CF5-A2EA-CDB02C4CEA38Q50960420-4552C7F5-C679-4A1A-90DF-58C8D6BD2C99Q50983851-255AB259-6434-4FBA-BD85-FAC20912CA28Q51602096-4567237D-6B2E-49EC-913F-0F3AD75CF6A3Q52294820-7CF3621C-BB4A-41E5-80EE-F7F072D8003CQ53544427-5854D3EE-BFAE-41BE-B610-21AF00ECCDFDQ57815855-9E597ED1-90D0-4E44-B3A8-1019368C90E8Q58582842-F9F21480-865B-449A-83D2-D20E534C502EQ58697103-E7462D7E-7D0A-4F18-9397-C83FCA07E837
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nonlinear pharmacokinetics: clinical Implications.
@en
Nonlinear pharmacokinetics: clinical Implications.
@nl
type
label
Nonlinear pharmacokinetics: clinical Implications.
@en
Nonlinear pharmacokinetics: clinical Implications.
@nl
prefLabel
Nonlinear pharmacokinetics: clinical Implications.
@en
Nonlinear pharmacokinetics: clinical Implications.
@nl
P1476
Nonlinear pharmacokinetics: clinical Implications.
@en
P2093
P304
P356
10.2165/00003088-199120060-00001
P577
1991-06-01T00:00:00Z
P6179
1014347289